Mesoblast's Heart Failure Candidate Shows Treatment Benefit In High-Risk Patients

Mesoblast Limited MESO announced new analyses from the landmark DREAM-HF Phase 3 trial of rexlemestrocel-L in HFrEF patients with diabetes and/or ischemia who are at high risk of cardiovascular mortality, heart attacks, or strokes.

  • In recent guidance to Mesoblast, FDA confirmed that reduction in the incidence of cardiovascular mortality or irreversible morbidity is a clinically meaningful acceptable endpoint and encouraged Mesoblast to identify the highest-risk group with the greatest likelihood of beneficial response.
  • Mesoblast performed additional analyses of MACE outcomes in pre-specified high-risk patient groups.
  • A single rexlemestrocel-L dose on top of maximal standard of care therapies reduced the composite 3-point MACE in all 537 patients by 33% over a mean follow-up of 30 months.
  • A hierarchical analysis across pre-specified high-risk subgroups showed the most significant benefit in diabetes and/or myocardial ischemia patients.
  • Rexlemestrocel-L, added to optimal standard of care therapies, reduced the 3-point MACE composite of cardiovascular death or heart attack or stroke by 37% across all HFrEF patients with diabetes and/or ischemia and by 54% in HFrEF patients with systemic inflammation.
  • Related Link: Mesoblast's Remestemcel Shows Promising Action In Patients With Heart Failure
  • Price Action: MESO shares closed 5.57% higher at $5.50 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsHeart FailurePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!